Bortezomib enhances fatty liver preservation in Institut George Lopez-1 solution through adenosine monophosphate activated protein kinase and Akt/mTOR pathways

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 1, 2014, Pages 62-72

  Bejaoui, Mohamed ^a   Zaouali, Mohamed Amine ^a   Folch Puy, Emma ^a   Pantazi, Eirini ^a   Bardag Gorce, Fawzia ^b   Carbonell, Teresa ^c   Oliva, Joan ^b   Rimola, Antoni ^c   Abdennebi, Hassen Ben ^d   Rosellõ Catafau, Joan ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

AMPK; bortezomib; ischaemia reperfusion injury; liver preservation; steatosis

Indexed keywords

ADENINE 9 ALPHA ARABINOFURANOSIDE; ADENOSINE MONOPHOSPHATE ACTIVATED PROTEIN KINASE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; INSTITUT GEORGE LOPEZ 1 SOLUTION; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOPROTEIN; PRESERVATIVE; PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE ACID SYNTHESIS; COLD ISCHEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FATTY LIVER; LIVER FUNCTION; LIVER PROTECTION; NONHUMAN; RAT; REPERFUSION INJURY; TISSUE PRESERVATION; VASCULAR RESISTANCE; WESTERN BLOTTING;

AMPK; BORTEZOMIB; ISCHAEMIA REPERFUSION INJURY; LIVER PRESERVATION; STEATOSIS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BORONIC ACIDS; FATTY LIVER; LIVER; ORGAN PRESERVATION; ORGAN PRESERVATION SOLUTIONS; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; RATS; RATS, ZUCKER; REPERFUSION INJURY; SOLUTIONS; TOR SERINE-THREONINE KINASES;

EID: 84890975298     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12154     Document Type: Article

References (46)

1. Fukumori T, et al. Why is a liver with steatosis susceptible to cold ischemic injury. Transplant Proc 1999; 31: 548-549.
2. Brunt EM, Tiniakos DG,. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16: 5286-5296.
3. Ben Mosbah I, et al. Preservation of steatotic livers in IGL-1 solution. Liver Transpl 2006; 12: 1215-1223.
4. Ramalho FS, et al. Hepatic microcirculatory failure. Acta Cir Bras 2006; 21 (Suppl 1): 48-53.
5. Ciechanover A, Schwartz AL,. The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim Biophys Acta 2004; 1695: 3-17.
6. Finley D, et al. Ubiquitin as a central cellular regulator. Cell 2004; 116: S29-S32. 22 p following S32.
7. Ciechanover A, Iwai K,. The ubiquitin system: from basic mechanisms to the patient bed. IUBMB Life 2004; 56: 193-201.
8. Herrmann J, et al. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res 2004; 61: 11-21.
9. Majetschak M, et al. Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model. Biochem Biophys Res Commun 2008; 365: 882-888.
10. Zaouali MA, et al. Proteasome inhibitors protect the steatotic and non-steatotic liver graft against cold ischemia reperfusion injury. Exp Mol Pathol 2013; 94: 352-359.
11. Ramachandran S, et al. Ischemia-reperfusion injury in rat steatotic liver is dependent on NFkappaB P65 activation. Transpl Immunol 2012; 26: 201-206.
12. Padrissa-Altes S, et al. The use of a reversible proteasome inhibitor in a model of Reduced-Size Orthotopic Liver transplantation in rats. Exp Mol Pathol 2012; 93: 99-110.
13. Baker TA, et al. Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation. Biochem Biophys Res Commun 2010; 401: 548-553.
14. Geng Q, et al. A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia. Biochem Biophys Res Commun 2009; 390: 1136-1141.
15. Campbell B, et al. Cardioprotective effects of a novel proteasome inhibitor following ischemia and reperfusion in the isolated perfused rat heart. J Mol Cell Cardiol 1999; 31: 467-476.
16. Bouma HR, et al. AMP-activated protein kinase as a target for preconditioning in transplantation medicine. Transplantation 2010; 90: 353-358.
17. Ben Mosbah I, et al. Addition of adenosine monophosphate-activated protein kinase activators to University of Wisconsin solution: a way of protecting rat steatotic livers. Liver Transpl 2007; 13: 410-425.
18. Al-Hakim AK, et al. Control of AMPK-related kinases by USP9X and atypical Lys(29)/Lys(33)-linked polyubiquitin chains. Biochem J 2008; 411: 249-260.
19. Zungu M, et al. Regulation of AMPK by the ubiquitin proteasome system. Am J Pathol 2011; 178: 4-11.
20. Padrissa-Altes S, et al. Ubiquitin-proteasome system inhibitors and AMPK regulation in hepatic cold ischaemia and reperfusion injury: possible mechanisms. Clin Sci (Lond) 2012; 123: 93-98.
21. Zaouali MA, et al. Improved rat steatotic and nonsteatotic liver preservation by the addition of epidermal growth factor and insulin-like growth factor-I to University of Wisconsin solution. Liver Transpl 2010; 16: 1098-1111.
22. Zaouali MA, et al. Insulin like growth factor-1 increases fatty liver preservation in IGL-1 solution. World J Gastroenterol 2010; 16: 5693-5700.
23. Zaouali MA, et al. Melatonin protects steatotic and nonsteatotic liver grafts against cold ischemia and reperfusion injury. J Pineal Res 2011; 50: 213-221.
24. Massip-Salcedo M, et al. Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin in rat steatotic liver undergoing ischemia-reperfusion. Hepatology 2008; 47: 461-472.
25. Padrissa-Altes S, et al. AMP-activated protein kinase as a target for preconditioning in transplantation medicine. Transplantation 2010; 90: 1241-1242.
26. Bardag-Gorce F, et al. Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease. Exp Mol Pathol 2011; 90: 123-130.
27. Niizuma K, et al. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem 2009; 109: 133-138.
28. Cantley LC,. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
29. Mullonkal CJ, Toledo-Pereyra LH,. Akt in ischemia and reperfusion. J Invest Surg 2007; 20: 195-203.
30. Amanso AM, et al. Proteasome inhibition represses unfolded protein response and Nox4, sensitizing vascular cells to endoplasmic reticulum stress-induced death. PLoS ONE 2011; 6: e14591.
31. Leclerc GM, et al. AMPK-induced activation of Akt by AICAR is mediated by IGF-1R dependent and independent mechanisms in acute lymphoblastic leukemia. J Mol Signal 2010; 5: 15-28.
32. Lieberthal W, et al. AMPK protects proximal tubular cells from stress-induced apoptosis by an ATP-independent mechanism: potential role of Akt activation. Am J Physiol Renal Physiol 2011; 301: F1177-F1192.
33. Abu-Amara M, et al. The nitric oxide pathway-evidence and mechanisms for protection against liver ischaemia reperfusion injury. Liver Int 2012; 32: 531-543.
34. Zaouali MA, et al. Hypoxia inducible factor-1alpha accumulation in steatotic liver preservation: role of nitric oxide. World J Gastroenterol 2010; 16: 3499-3509.
35. Ben Abdennebi H, et al. How to protect liver graft with nitric oxide. World J Gastroenterol 2011; 17: 2879-2889.
36. Ouchi N, et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004; 279: 1304-1309.
37. Morrow VA, et al. Direct activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in human aortic endothelial cells. J Biol Chem 2003; 278: 31629-31639.
38. Chen H, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026.
39. Hwang SK, Kim HH,. The functions of mTOR in ischemic diseases. BMB Rep 2011; 44: 506-511.
40. Khan S, et al. Rapamycin confers preconditioning-like protection against ischemia-reperfusion injury in isolated mouse heart and cardiomyocytes. J Mol Cell Cardiol 2006; 41: 256-264.
41. Vigneron F, et al. GSK-3beta at the crossroads in the signalling of heart preconditioning: implication of mTOR and Wnt pathways. Cardiovasc Res 2011; 90: 49-56.
42. Hernandez G, et al. A novel cardioprotective p38-MAPK/mTOR pathway. Exp Cell Res 2011; 317: 2938-2949.
43. Aoyagi T, et al. Cardiac mTOR protects the heart against ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2012; 303: H75-H85.
44. Yang XM, et al. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004; 44: 1103-1110.
45. Juhaszova M, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 2004; 113: 1535-1549.
46. Chen FT, et al. The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina. PLoS ONE 2013; 8: e64262.